Antibody-drug conjugates in hematologic malignancies
Comprehensive overview of approved and pipeline antibody-drug conjugates for blood cancers clarifies unique toxicity profiles guiding clinical deployment.
This comprehensive review from Sarah Cannon Research Institute summarizes the clinical development landscape of antibody-drug conjugates across all hematologic malignancies, covering 6 approved agents and their unique toxicity profiles, providing useful context for pipeline handoff given multiple T1 and T6 watchlist articles involving ADC strategies. Contextualizes the novel ADC findings from this run (ABBV-706, anti-LILRB4 STAR-T) within the broader hematologic ADC landscape.
What the study was
- Study design
- Narrative review
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cancer
Why it surfaced
Useful pipeline context document for hematologic ADC landscape; published in Cancer Supplement alongside multiple ADC reviews providing a coordinated knowledge base.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.